KDR and cancer: Mesylate apatinib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), has been used for the treatment of various types of cancers due to its antiangiogenic role via competition for the ATP-binding site of VEGFR2 [9].